Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 36

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 36
---
At the time a holder
exercises its December 2023 Private Placement Pre-Funded Warrants, in lieu of making the cash payment otherwise contemplated to be made
to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either
in whole or in part) the net number of Depositary Shares determined according to a formula set forth in the December 2023 Private Placement
Pre-Funded Warrants.

Exercise Price.The
exercise price of each Series E Warrant, December 2023 Underwriter Warrant and December 2023 Private Placement Pre-Funded Warrant is
$550.00, $625.00 and $0.025 per Depositary Share.

Beneficial Ownership Limitation.A holder shall have no right to exercise any portion of a warrant, to the extent that, after giving effect to such exercise,
such holder, together with such holder’s affiliates, and any persons acting as a group together with such holder or any such affiliate,
would beneficially own in excess of 9.99% (or in the case of the December 2023 Underwriter Warrants, 4.99%), of the number of Ordinary
Shares outstanding immediately after giving effect to the issuance of the Ordinary Shares underlying the Depositary Shares upon such
exercise. The holder of the warrant, upon notice to us, may increase or decrease the beneficial ownership limitation to a percentage
not to exceed 9.99%, provided that any increase in the beneficial ownership limitation shall not be effective until 61 days following
notice to us. Beneficial ownership of the holder and its affiliates will be determined in accordance with Section 13(d) of the Exchange
Act, and the rules and regulations promulgated thereunder.

Stock dividends and stock splits.If we pay a stock dividend or otherwise make a distribution payable in Depositary Shares or Ordinary Shares, or any
other equity or equivalent securities, subdivide or combine outstanding Depositary Shares or Ordinary Shares, or reclassify Depositary
Shares, Ordinary Shares or any shares of our capital stock, the exercise price of each warrant will be adjusted by multiplying the then
exercise price by a fraction, the numerator of which shall be the number of Depositary Shares (excluding treasury shares, if any) outstanding
immediately before such event, and the denominator of which shall be the number of Depositary Shares outstanding immediately after such
event.

Rights Offerings; pro rata distributions.If we issue Ordinary Share equivalents or rights to purchase shares, warrants